Clinical Trial Search

Primary: Mean Change From Baseline in 24-Hour Heart Rate at Days 20 and 48 — -1.86; 6.65; 13.50; 15.80 beats/minute

Primary: Percentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12) — 97.2 percentage of participants

Primary: Number of Participants Confident in the Use of EHealth Format — 7 Participants

Primary: Number of Patients With Hyperglycemia in the Intensive Care Unit (ICU) — 76; 68 Participants

Primary: Percentage of Participants With Headache Response — 57.0; 35.8; 49.3; 35.3 percentage of participants — p=<0.0001

Primary: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831 — 714.8; 597.5; 4563; 4665…

Primary: the Incidence of Clinically Significant Displacement of DLTs During Change of Patient Position — 17; 18 Participants

Primary: Time to Recovery (TTR) of Participant Train Of Four (TOF) Ratio to ≥0.9: Primary Kaplan-Meier Analysis — 1.7; 1.8; 1.8; 3.4 Minutes — p=0.0075

Primary: Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month — -25.2; -29.9; -58.9 micrometers — p=0.04

Primary: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) — 17; 50; 50 Participants — p=< 0.001

Primary: Change in Non-displaceable Binding Potential (BP-ND) in the TAK-041+AMPH Condition Compared to AMPH Alone — 17; 36; 14; 23 percentage of reduction

Primary: Change in Strength — -4.0 Nm/kg

Primary: Number of Participants With Serious and Non-serious Adverse Events — 6; 4 Participants

Primary: Maximum Drug Concentration of Metformin in Plasma After Single Dose Administration (Cmax) — 1550; 1460 microgram per liter (mcg/L)

Primary: Percent Change From Baseline in Lipoprotein Lp(a) Plasma Concentration at Day 85/Day 99 — -3.7; -44.5; -70.0; -5.6 percent change — p=<.001